GlassScriptPhysician profile
Jennifer Fox
NPI 1649789462
$1,460.62
in general payments reported to CMS, 2019-2025
22 companies · $625 in 2025
The $625 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.44 · 2022: $311 · 2023: $227 · 2024: $237 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,090.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $272.44 | 2023-2025 | Inspire |
| Genzyme Corporation | $174.71 | 2023-2025 | |
| Aerin Medical INC. | $166.26 | 2025 | |
| Glaxosmithkline, LLC. | $138.37 | 2023-2025 | Nucala |
| Optinose US, INC. | $105.97 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.69 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $77.54 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $62.41 | 2022 | |
| Medtronic, INC. | $59.43 | 2023-2024 | Sinuva, Propel |
| Janssen Pharmaceuticals, INC | $50.43 | 2022-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $36.21 | 2022 | |
| Esperion Therapeutics, INC. | $32.97 | 2022 | |
| Edwards Lifesciences Corporation | $29.92 | 2021 | |
| Pfizer INC. | $23.90 | 2022 | |
| Amgen INC. | $21.72 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $18.86 | 2024 | |
| Kaleo, INC. | $18.07 | 2024 | Auvi-Q |
| Kci USA, INC. | $17.31 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $16.98 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $14.44 | 2022 | |
| Hikma Pharmaceuticals USA | $12.78 | 2023 | Ryaltris |
| Abbott Laboratories | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.